- Home
- ACET vs OKYO Comparison
ACET vs OKYO Comparison
Compare ACET & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACET | OKYO |
|---|---|---|
| Founded | 1947 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 83.4M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACET | OKYO |
|---|---|---|
| Price | $7.73 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $48.33 | $6.33 |
| AVG Volume (30 Days) | ★ 136.8K | 81.7K |
| Earning Date | 05-06-2026 | 07-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.31 |
| 52 Week High | $9.05 | $3.35 |
Technical Indicators
Market Signals| Indicator | ACET | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 45.58 |
| Support Level | $6.28 | $1.50 |
| Resistance Level | $8.46 | $1.73 |
| Average True Range (ATR) | 0.47 | 0.12 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 57.30 | 37.50 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.